Products from BPS Bioscience require a minimum order value above 400€
Background: SARS-COV-2 Variant B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This variant, also known as 501Y.V2, has many mutations which may lead to higher transmissibility and infectivity. In particular, the B.1.351 variant contains three mutations within the RBD region of the Spike S1 protein: K417N, E484K, and N501Y. Investigating the effect of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification.
Formulation: 8mM phosphate pH 7.4, 110mM NaCl, 2.2mM KCl, and 20% glycerol.
Genbank: MN908947
Purity: ≥90%
Storage Stability: At least 6 months at -80°C.
Supplied As: Aqueous buffer solution.
Tags: C-terminal Avi-His-tag
Uniprot: P0DTC2
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
English
Deutsch
